To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Autolus Therapeutics logo Autolus Therapeutics (NASDAQ:AUTL) executives highlighted a "very good first year of launch" for AUCATZYL during the company's fourth- quarter and full-year 2025 financial results call, pointing to $74.3 million in revenue recognized in 2025, expanded U.S. treatment-center activation, and early real-world outcomes that management said aligned well with prior clinical trial results. Commercial launch update and 2026 outlook Chief Executive Officer Dr. Christian Itin said the company ...

Autolus Therapeutics (NasdaqGS:AUTL) Q4 2025 Earnings call March 27, 2026 08:30 AM ET Company ParticipantsAmanda Cray - Executive Director of Investor RelationsChristian Itin - CEOEmily Bodnar - VP of Equity ResearchJames Shin - Director of Biopharma Equity ResearchMatt Phipps - Partner and Group Head of Biotechnology Equity ResearchRob Dolski - CFOSalim Syed - Managing DirectorConference Call ParticipantsGil Blum - Senior AnalystYanan Zhu - Senior Biotech AnalystNone - AnalystOperatorGood day and thank you ...

Autolus Therapeutics (NasdaqGS:AUTL) Q4 2025 Earnings call March 27, 2026 08:30 AM ET Speaker6Good day, and thank you for standing by. Welcome to the Autolus fourth quarter 2025 and full year 2025 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star one one on your telephone. You will then hear an automated message advising your ...

Q4 2025 Financial Results and Business Updates March 27, 2026 For Investor communication only. Not for use in product promotion. Not for further distribution. 3 • Welcome and Introduction: Amanda Cray, ED, Investor Relations & External Communications • Operational Highlights: Dr. Christian Itin, CEO • Financial Results: Rob Dolski, CFO • Upcoming Milestones and Conclusion: Dr. Christian Itin, CEO • Q&A: Dr. Christian Itin and Rob Dolski Developing and Delivering a New Generation of T Cell Therapies Strong f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2026 (Former name or former address, if changed since last report) Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of (Commission File Number) (I.R.S. Employer Identification No.) T ...

AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025AUCATZYL® UK launch underway following successful National Institute for Health and Care Excellence (NICE) evaluationAutolus continues to expect full year 2026 AUCATZYL® net product revenue of $120 million to $135 million and shift to positive gross margin to occur in 2026Independent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - Autolus Therapeutics plc is set to release its fourth quarter and full year 2025 financial results and operational highlights on March 27, 2026, before the U.S. market opens [1] Group 1: Financial Results Announcement - The financial results will be discussed in a conference call and webcast scheduled for 8:30am EDT / 12:30pm GMT on the same day [2] - Participants are required to pre-register to receive dial-in numbers and a personal PIN for accessing the conference call [2] Group 2: Company Overview - Autolus Therapeutics plc is a commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering next-generation T cell therapies for cancer and autoimmune diseases [3] - The company utilizes proprietary and modular T cell programming technologies to create targeted and controlled T cell therapies [3] - Autolus has a marketed therapy named AUCATZYL and a pipeline of candidates aimed at treating hematological malignancies, solid tumors, and autoimmune diseases [3]

Summary of Autolus Therapeutics FY Conference Call Company Overview - **Company**: Autolus Therapeutics (NasdaqGS:AUTL) - **Product Launched**: Catsl, a CD19 CAR-T product approved for acute leukemia patients, specifically in the relapsed refractory adult population - **First Year Revenue**: $75 million, achieving market leadership quickly after launch [1][2] Key Points and Arguments Product Launch and Market Position - **Launch Timeline**: Began at the start of the previous year, achieving market leadership by Q2 [2] - **Regulatory Approvals**: Received approvals in the U.K. and Europe, including a positive NICE review, allowing routine commissioning without additional data collection [2] - **Market Access**: Successfully launched in the U.K. at the end of the previous year [2] Manufacturing and Supply Chain - **Manufacturing Facility**: Established a facility in the U.K. with a manufacturing success rate above 90%, which is notable for a first-year launch [4][5] - **Optimization Efforts**: Focus on optimizing manufacturing operations to reduce costs and improve gross margins over the next 24-36 months [6] - **Current Capacity**: No capacity limitations reported, with plans to expand to over 80 centers in the U.S. [6][9] Clinical Data and Safety Profile - **Real-World Data Collection**: Collaborating with the ROCCA Consortium to collect clinical data, with 60% of patients captured in the database [9][10] - **Safety Profile**: Reported zero high-grade CRS and only 3% high-grade ICANS, indicating a favorable safety profile compared to competitors [10][11] - **Response Rates**: Over 90% response rate in real-world settings, with a 78% response rate in the FELIX study [11] Expansion Opportunities - **Additional Indications**: Ongoing pivotal studies in pediatric patients and lupus nephritis, with exploratory studies in progressive MS [3][12] - **Market Potential**: The lupus nephritis market is sizable, with 25,000-35,000 patients refractory to standard care, significantly larger than the acute leukemia market [27] Future Milestones - **Upcoming Studies**: Expecting initial data from the MS study and pivotal studies in pediatrics and lupus nephritis by 2028 [33][34] - **Market Access in Europe**: Currently negotiating for market access in Europe, with no revenue guidance provided yet [34] Additional Important Insights - **Patient Demographics**: The majority of patients in the progressive MS study are young females, indicating a high demand for effective treatments [31] - **Unique Mechanism of Action**: The CAR-T product has a differentiated mechanism that allows for higher potency and reduced toxicity, which is crucial for expanding into autoimmune diseases [15][19] - **Established Infrastructure**: The company has a reliable manufacturing infrastructure that reduces capital needs for entering new indications [20] This summary encapsulates the critical aspects of Autolus Therapeutics' conference call, highlighting the company's achievements, future plans, and the potential market landscape for its products.